RE:RE:ONCY May 09, 2024 Earnings CallTranscript " On the topic of our upcoming Type C meeting, as Matt indicated, defining the registrational path for pela in breast cancer is a major goal for Oncolytics in 2024."
" our registrational plans for pela in pancreatic cancer...will focus on pela in combination with atezolizumab, gemcitabine and nab-paclitaxel in patients receiving first-line treatment for metastatic pancreatic cancer. We continued to develop a study protocol that utilizes an adaptive design building on the positive results from cohort 1 of the GOBLET study. We expect to provide an update on these plans this quarter."
" Positive results from the expanded anal cancer cohort may open the door to an accelerated registrational path, a modest expansion of fewer than 28 patients is expected to be sufficient to confirm the benefit we've seen so far and to provide the basis for a registrational study which we anticipate will be the next logical step."